ACTU
Actuate Therapeutics Inc NASDAQ Listed Aug 13, 2024$2.07
+0.98%
vs $2.05
Mkt Cap $49.5M
52w Low $1.58
6.4% of range
52w High $9.22
50d MA $2.40
200d MA $4.84
P/E (TTM)
-1.9x
EV/EBITDA
—
P/B
5.5x
Debt/Equity
0.1x
ROE
-280.5%
P/FCF
-2.3x
RSI (14)
52.90
ATR (14)
$0.24
Beta
0.86
50d MA
$2.40
200d MA
$4.84
Avg Volume
157.7K
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
CIK (SEC)
Phone
817 887 8455
1751 River Run · Fort Worth, TX 76107 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | AMC | -0.23 | -0.24 | -4.3% | 2.90 | -0.7% | -9.7% | -7.3% | -1.2% | +4.6% | -3.6% | — |
| Mar 26, 2026 | AMC | -0.24 | -0.18 | +25.0% | 2.27 | -0.9% | -5.3% | +6.5% | +19.7% | -9.1% | -0.4% | — |
| Nov 13, 2025 | AMC | -0.27 | -0.25 | +7.4% | 5.88 | +0.5% | +0.5% | +0.2% | +3.0% | -4.1% | +4.1% | — |
| Aug 14, 2025 | AMC | -0.19 | -0.30 | -57.9% | 8.22 | -2.9% | -1.2% | +1.6% | -3.4% | -3.6% | -0.1% | — |
| May 15, 2025 | AMC | -0.30 | -0.32 | -6.7% | 9.76 | +0.3% | +8.1% | -2.7% | +3.3% | +3.6% | -8.0% | — |
| Mar 13, 2025 | AMC | -0.29 | -0.33 | -13.8% | 7.45 | -1.6% | -2.7% | +2.1% | +0.8% | -1.5% | -4.9% | — |
| Nov 13, 2024 | AMC | -0.55 | -0.55 | +0.0% | 8.56 | +2.0% | -0.1% | +1.5% | +3.2% | -0.7% | -3.6% | — |
| Sep 24, 2024 | AMC | — | -4.20 | — | 6.52 | +0.0% | -11.0% | +4.7% | +3.3% | +18.8% | -7.1% | — |
| Mar 31, 2024 | AMC | — | -0.54 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.50 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.41 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.39 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.39 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.27 | $2.38 | +4.8% | +22.5% | -9.0% | +17.4% | -4.0% | +1.8% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.72 | +0.0% | +5.8% | +14.3% | +3.4% | +0.0% | +7.4% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.10 | $5.95 | -2.5% | -4.1% | +4.1% | +3.6% | -0.8% | -0.2% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.09 | $7.19 | +1.4% | -3.0% | +2.0% | -5.3% | +3.6% | -1.7% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.12 | $8.12 | +0.0% | +1.6% | -3.4% | -3.6% | -0.1% | +9.0% |
No insider trades available.
8-K
Actuate Therapeutics Inc -- 8-K Filing
May 22
8-K · 7.01
! Medium
Actuate Therapeutics Inc -- 8-K 7.01: Regulation FD Disclosure
Actuate Therapeutics disclosed updated corporate presentation materials via press release, suggesting potential strategic communications or operational updates for investor consideration.
May 11
8-K · 5.02
!!! Very High
Actuate Therapeutics Inc -- 8-K 5.02: Executive Change
Martin H. Huber's simultaneous appointment and resignation as a Class III director at Actuate Therapeutics suggests a routine board reclassification or procedural change rather than material leadership disruption for ACTU shareholders.
May 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bios Capital Management, Lp | 10,049,996 | $62M | — | Dec 2025 |
| 2 | Voss Capital, Lp | 1,725,000 | $5M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 400,529 | $1M | New | Mar 2026 |
| 4 | Connective Capital Management, Llc | 113,266 | $310K | New | Mar 2026 |
| 5 | Northern Trust Corp | 97,851 | $268K | Reduced | Mar 2026 |
| 6 | Morgan Stanley | 26,238 | $161K | Added | Dec 2025 |
| 7 | Vanguard Portfolio Management Llc | 55,536 | $152K | New | Mar 2026 |
| 8 | Northwestern Mutual Wealth Management Co | 18,518 | $113K | Reduced | Dec 2025 |
| 9 | Jane Street Group, Llc | 16,625 | $102K | New | Dec 2025 |
| 10 | Aqr Capital Management Llc | 27,109 | $74K | New | Mar 2026 |
| 11 | Royal Bank Of Canada | 22,225 | $61K | Reduced | Mar 2026 |
| 12 | Eversource Wealth Advisors, Llc | 2,519 | $58K | Added | Mar 2026 |
| 13 | Bank Of New York Mellon Corp | 15,416 | $42K | Added | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 11,034 | $30K | Added | Mar 2026 |
| 15 | Fmr Llc | 8,945 | $25K | Added | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 5,889 | $16K | New | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 3,863 | $9K | Added | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 2,492 | $7K | Added | Mar 2026 |
| 19 | Barclays Plc | 2,176 | $6K | Reduced | Mar 2026 |
| 20 | Ubs Group Ag | 1,951 | $5K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$49.5M
Enterprise Value
$30.8M
P/E (TTM)
-1.95x
Forward P/E
—
PEG Ratio
0.09x
P/B
5.49x
P/S
—
P/FCF
-2.27x
EV/EBITDA
—
Shares Out
21.0M
Financials (TTM)
Revenue
$0
Net Income
-$22.2M
EBITDA
-$22.5M
Free Cash Flow
-$19.2M
Op Cash Flow
-$19.2M
EPS Basic
$-1.06
EPS Diluted
$-1.06
EPS Forward
$-0.73
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$14.0M
Total Liab.
$6.1M
Total Equity
$7.9M
Cash
$13.2M
LT Debt
$405K
Book Value/Sh
$0.38
Debt/Equity
0.05x
Current Ratio
2.39
Quick Ratio
2.39
Returns & Growth
ROE
-280.5%
ROA
-158.4%
ROIC
-270.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+67.5%
Price Returns
2W
-30.3%
1M
-31.3%
3M
-46.0%
6M
-73.5%
12M
-83.0%
Technicals
52W High
$9.22
52W Low
$1.58
50d MA
$2.40
200d MA
$4.84
RSI (14)
52.90
ATR (14)
$0.24
Beta
0.86
Avg Volume
158K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.00
High
$21.00
Low
$21.00
Median
$21.00
Data updated apr 24, 2026 10:44am
· Source: financialmodelingprep.com